



<b>IN CASE OF EMERGENCY</b> <b>Emergency Phone: (614) 276-4000</b>
---

## Material Safety Data Sheet

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION		
Common/Trade Name: Cilostazol Tablets 50 mg and 100 mg		
Chemical Name: 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone		
Synonyms: None		
Molecular Formula: C <sub>20</sub> H <sub>27</sub> N <sub>5</sub> O <sub>2</sub>		
Molecular Weight: 369.47		
CAS No: 73963-72-1		
Chemical Family: Cyclic cAMP phosphodiesterase inhibitor		
Product Use: Treatment of intermittent claudication		
Manufacturer's Name: <b>Boehringer Ingelheim Roxane Inc.</b>		
Address: 1809 Wilson Road Columbus, Ohio 43228		
2. COMPOSITION / INFORMATION ON INGREDIENTS		
Composition	CAS#	Exposure Limit
Cilostazol (active ingredient)	73963-72-1	None established
<i>REFER to PHYSICIAN'S DESK REFERENCE for common components present as &lt;1%</i>		
3. HAZARDS IDENTIFICATION		
Emergency Overview	Physical State: Round tablets The 50 mg tablets are white with "54 521" debossed on one side and blank on the other. The 100 mg tablets are white with "54 757" debossed on one side and blank on the other.  Odor: None  <b>WARNING!</b> May be harmful if swallowed. Accidental ingestion of large amounts may be fatal.	
Primary Route(s) of Entry	Ingestion	
Potential Health Effects:	Inhalation: Not expected to be an inhalation hazard in final pharmaceutical form.  Eye Contact: Not expected to be a hazard to the eye in final pharmaceutical form.  Skin Contact: Not expected to be a hazard to the skin. Can cause hypersensitive reactions resulting in rash, redness, itching and inflammation.  Ingestion: May be harmful if ingested. Ingestion may cause asthenia, hypertension, vomiting, rash, urinary tract infection and hypertension.	
Toxicity Data:	See Section 11	
Effects of Overexposure:	The potential for exposure is reduced in finished pharmaceutical form. Overexposure by ingestion may cause severe headache, diarrhea, hypotension, and possible cardiac arrhythmias.	
Target Organs:	Gastrointestinal tract, Muscular System	
4. FIRST AID MEASURES		
Eye Exposure	Any material that contacts the eye should be washed out immediately with water. If easy to do, remove contact lenses if worn. Get medical attention if symptoms persist.	
Skin Exposure	Wash with soap and water. Get medical attention if symptoms occur.	

Ingestion	Call a physician or poison control center immediately.				
Inhalation	Should not pose a hazard in the final form. If breathing is difficult, move to fresh air. Get medical attention immediately.				
<b>5. FIRE AND EXPLOSION HAZARDS</b>					
Flammability	Lower: N/A		Upper: N/A		
Flash Point	Not available				
Extinguishing Media	Use water spray, dry chemical, carbon dioxide or material appropriate for fire in surrounding area				
Special Fire Fighting Procedures	Wear full protective clothing and self-contained breathing apparatus.				
Unusual Fire/Explosion Hazards	Not Applicable				
Hazardous Combustion Products	Carbon dioxide, carbon monoxide, oxides of nitrogen				
<b>6. ACCIDENTAL RELEASE INFORMATION</b>					
STEPS TO BE TAKEN IF SIGNIFICANT QUANTITIES OF PRODUCT IS SPILLED: Use appropriate personal protective equipment (see Section 8). Sweep up and containerize spill material in a compatible container. Dispose according to applicable regulations. Incineration of the waste at an approved facility is recommended.					
<b>7. PRECAUTIONS FOR SAFE HANDLING AND USE</b>					
Precautions Handling Significant Quantities of Product:	Observe good industrial hygiene practices				
Storage	Store at 20 to 25°C (68°F to 77°F). Keep container closed tightly. Protect from light and moisture. Store away from foodstuffs.				
<b>8. CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT</b>					
Exposure Limits	None				
Engineering Controls	Not required when handling tablets or containers. Ventilation should be matched to conditions.				
Respiratory Protection	Not required when handling tablets or containers. NIOSH/MSHA approved respirators for protection should be used if respirators are found to be necessary. Ventilation should be matched to conditions.				
Personal Protection	Not required when handling tablets. If containers are compromised or exposure is likely wear: Goggles, Lab Coat, Gloves				
Recommended Facilities	Eye wash, washing facilities				
<b>9. PHYSICAL / CHEMICAL CHARACTERISTICS</b>					
Appearance	White, round tablets	Melting point	Not available	Solubility in water	Good (active)
Odor	None	Boiling point	Not available	Specific Gravity	Not available
Taste	Not available	Vapor Pressure	Not available	Flashpoint	Not available
pH	Not available	Density	Not available	Flammability Limits	Not available
<b>10. STABILITY AND REACTIVITY DATA</b>					
Stability	Stable				
Incompatibility	None known				
Hazardous Decomposition	Oxides of carbon, oxides of nitrogen				
Conditions to Avoid	Excessive heat, light				
Hazardous Polymerization	Will not occur.				

<b>11. TOXICOLOGICAL INFORMATION</b>	
<p><b>Acute Toxicity:</b></p> <p><b>Active Ingredient:</b>                      Oral LD50 (rat): &gt;5000 mg/kg                      Oral LD50 (mouse): &gt;5000 mg/kg</p> <p><b>Carcinogenicity:</b> Not listed as a carcinogen by NTP, IARC Monographs or OSHA.</p>	
<b>12. ENVIRONMENTAL IMPACT INFORMATION</b>	
No information is currently available on the environmental impact of this product.	
<b>13. DISPOSAL INFORMATION</b>	
<p><b>Waste Disposal Considerations:</b> Dispose of material according to federal, state and local disposal regulations or company operating procedures. Disposal by incineration is recommended.                      At home: Discard away from children's reach.</p>	
<b>14. TRANSPORTATION INFORMATION</b>	
<p>This product is not subject to the regulations for the safe transport of hazardous chemicals.                      DOT: Not regulated                      TDG: Not regulated                      IATA: Not regulated                      IMDG: Not regulated</p>	
<b>15. REGULATORY INFORMATION</b>	
<p><b>DEA:</b> Cilostazol is not a controlled substance.</p> <p><b>FDA:</b> Cilostazol is an approved prescription medication.</p> <p><b>Inventory Status:</b>                      This material is not listed on the US TSCA Inventory. Therefore, it can only be used for TSCA exempt purposes such as R&amp;D or drug use.                      This material is not listed on the DSL Inventory but is exempt.</p>	
<b>16. OTHER DATA</b>	
<p><b>ABBREVIATIONS:</b>                      N/A – not applicable</p>	
Prepared by: Boehringer Ingelheim Roxane Inc.	
<p><b>References:</b></p> <ol style="list-style-type: none"> <li>1. Cilostazol Tablets 50 mg and 100 mg, Package Insert, Boehringer Ingelheim Roxane Inc., Columbus, Ohio</li> <li>2. RTECS No. VC8277500 – 2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-</li> <li>3. Ariel Websight. Regulatory and ChemExpert Database.</li> <li>4. PDR – Physicians Desk Reference</li> </ol>	
Date: New MSDS: 10/29/2002	Revised: 9/24/2008
<b>SEE CURRENT PACKAGE INSERT FOR FURTHER INFORMATION</b>	

*The information provided is believed to be complete and accurate. If this product is combined with other materials, deteriorates or becomes contaminated, it may pose hazards not mentioned in this MSDS. It is the users' responsibility to use the information according to the application. Boehringer Ingelheim Roxane Inc. assumes no responsibility or liability resulting from the use of this information.*